BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16029057)

  • 1. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.
    Govindan SV; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Technol Cancer Res Treat; 2005 Aug; 4(4):375-91. PubMed ID: 16029057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
    Sharkey RM; Goldenberg DM
    J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-guided radiation therapy of cancer.
    Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
    Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antibody conjugates in cancer therapy.
    Govindan SV; Goldenberg DM
    ScientificWorldJournal; 2010 Oct; 10():2070-89. PubMed ID: 20953556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cancer therapy using radiolabeled monoclonal antibodies.
    Bethge WA; Sandmaier BM
    Technol Cancer Res Treat; 2005 Aug; 4(4):393-405. PubMed ID: 16029058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy for cancer.
    von Mehren M; Adams GP; Weiner LM
    Annu Rev Med; 2003; 54():343-69. PubMed ID: 12525678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
    White CA
    J Exp Ther Oncol; 2004 Dec; 4(4):305-16. PubMed ID: 15844660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
    Maloney DG; Press OW
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel radiolabeled antibody conjugates.
    Goldenberg DM; Sharkey RM
    Oncogene; 2007 May; 26(25):3734-44. PubMed ID: 17530026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer radioimmunotherapy.
    Sharkey RM; Goldenberg DM
    Immunotherapy; 2011 Mar; 3(3):349-70. PubMed ID: 21395378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
    DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.